You have no items in your shopping cart.
IL2 Antibody
Description
Research Area
Images & Validation
−| Tested Applications | ELISA, WB |
|---|---|
| Reactivity | Human |
Key Properties
−| Antibody Type | Primary Antibody |
|---|---|
| Host | Goat |
| Clonality | Polyclonal |
| Immunogen | Produced from sera of goats pre-immunized with highly pure (>98%) recombinant hIL-2 (human Interleukin-2). |
| Target | IL2 |
| Purification | Anti-hIL-2 specific antibody was purified by affinity chromatography employing immobilized hIL-2 matrix. |
| Conjugation | Unconjugated |
Storage & Handling
−| Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
|---|---|
| Form/Appearance | Lyophilized |
| Concentration | batch dependent |
| Disclaimer | For research use only |
Alternative Names
−Similar Products
−ZEB1/NIL2A Rabbit Polyclonal Antibody [orb6954]
FC, IF, IHC-Fr, IHC-P, WB
Bovine, Canine, Gallus, Porcine, Rabbit
Human, Mouse, Rat
Rabbit
Polyclonal
Unconjugated
50 μl, 100 μl, 200 μlAnti-IL-2R alpha (CD25) [Basiliximab] [orb348865]
Blocking, FC, IF, IHC, WB
Human, Primate
Human
Monoclonal
Unconjugated
0.2 mgAnti-IL-2R alpha (CD25) [Basiliximab] [orb348908]
Blocking, FC, IF, IHC, WB
Human, Primate
Human
Monoclonal
Unconjugated
0.2 mgAnti-IL-2R alpha (CD25) [Basiliximab] [orb1152522]
Blocking, FC, IF, IHC, WB
Human, Primate
Human
Monoclonal
Unconjugated
0.2 mg

Quality Guarantee
Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

To detect hIL-2 by sandwich ELISA (using 100 ul/well antibody solution) a concentration of 0.5 - 2.0 ug/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with Anti-Human IL-2 (orb1272462) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant hIL-2.

To detect hIL-2 by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 ug/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hIL-2 is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.

To detect hIL-2 by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 ug/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hIL-2 is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.

This antibody stained formalin-fixed, paraffin-embedded sections of human breast invasive ductal carcinoma. The recommended concentration is 0.5 ug/mL with an overnight incubation at 4°C. An HRP-labeled polymer detection system was used with a DAB chromogen. Heat induced antigen retrieval with a pH 6.0 sodium citrate buffer is recommended. Optimal concentrations and conditions may vary.

This antibody stained formalin-fixed, paraffin-embedded sections of human breast invasive ductal carcinoma. The recommended concentration is 0.5 ug/mL with an overnight incubation at 4°C. An HRP-labeled polymer detection system was used with a DAB chromogen. Heat induced antigen retrieval with a pH 6.0 sodium citrate buffer is recommended. Optimal concentrations and conditions may vary.
Documents Download
Request a Document
Protocol Information
IL2 Antibody (orb1272463)
Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.
Login to Submit a Review







![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb348865_1.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb348865_2.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb348865_3.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb348865_4.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb348865_5.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb348865_6.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb348908_1.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb348908_2.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb348908_3.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb348908_4.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb348908_5.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb348908_6.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb1152522_1.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb1152522_2.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb1152522_3.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb1152522_4.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb1152522_5.png)
![Anti-IL-2R alpha (CD25) [Basiliximab]](/images/pub/media/catalog/product/NewWebsite/35/orb1152522_6.png)
